<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00229515</url>
  </required_header>
  <id_info>
    <org_study_id>TSES-02-III</org_study_id>
    <nct_id>NCT00229515</nct_id>
  </id_info>
  <brief_title>Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI</brief_title>
  <official_title>Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Administered With the Single High-Dose Bolus Versus Abciximab and Sirolimus Eluting Stent Versus Bare Metal Stent in Acute Myocardial Infarction - MULTI-STRATEGY Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marco Valgimigli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Ferrara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which from the four combinations
      tirofiban+sirolimus eluting stent (SES), tirofiban+bare metal stent (BMS), abciximab+SES,
      abciximab+BMS is the possible gold standard treatment for ST-segment elevation myocardial
      infarction in terms of efficacy and cost-efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination abciximab plus bare metal stent (BMS) is currently considered the standard
      therapy for AMI. The use of sirolimus eluting stent (SES) is related to a reduction of the
      need for urgent target vessel revascularization (TVR). With current acquisition prices for
      abciximab and SES, replacing abciximab with tirofiban, administered as a single high-dose
      bolus (SHDB) regimen, is a promising strategy that would preserve financial resources. In a
      recent study the combination tirofiban and SES resulted to be associated to an overall lower
      major adverse cardiovascular events (MACE) rate with respect to the abciximab plus BMS.
      However, since no conclusion can be drawn yet regarding the relative contribution of a
      specific GP IIb/IIIa inhibitor or a stent type with respect to the other, the combination of
      abciximab and SES may be associated to an even lower event rate with respect to SHDB
      tirofiban and SES, thus offsetting the higher initial cost.

      Comparison(s): four strategies (SHDB tirofiban + BMS, SHDB tirofiban + SES, abciximab + BMS,
      abciximab + SES) are compared to determine the possible gold standard treatment for
      ST-segment elevation myocardial infarction in terms of efficacy and cost-efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evaluation of the degree of ST-segment resolution after the mechanical intervention.</measure>
    <time_frame>90 minutes after last balloon inflation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The cumulative rate of death for any cause, reinfarction and target vessel revascularisation</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death, recurrent acute myocardial infarction, target vessel revascularization and target lesion revascularisation, considered separately or in combination.</measure>
    <time_frame>at any time during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of the cost-effectiveness of the involved experimental treatments.</measure>
    <time_frame>8 months, 1,3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis according to the ARC classification</measure>
    <time_frame>any time during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the degree of cumulative or single lead ST segment resolution at time frames different from the primary endpoint. the degree of residual ST segment elevation.</measure>
    <time_frame>immediately after intervention, at 90 minutes and at discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding rate defined according to different classifications including TIMI, Acuity, GUSTO and Steeple.</measure>
    <time_frame>at 30 days, 1 year, 3 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">744</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive abciximab infusion at standard regimen prior undergoing percutaneous coronary intervention for STEMI followed by BMS implantation in the culprit lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abciximab followed by implantation of sirolimus-eluting stent in the culprit lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tirofiban infusion followed by bare metal stent implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tirofiban and sirolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>abciximab followed by implantation of bare metal stent</intervention_name>
    <description>Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Glycoprotein IIB/IIIa inhibitors</other_name>
    <other_name>Stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>abciximab and Sirolimus eluting stent</intervention_name>
    <description>Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion</description>
    <arm_group_label>2</arm_group_label>
    <other_name>glycoprotein IIb/IIIa inhibitors</other_name>
    <other_name>stent</other_name>
    <other_name>DES</other_name>
    <other_name>drug-eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tirofiban and bare metal stent</intervention_name>
    <description>Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation</description>
    <arm_group_label>3</arm_group_label>
    <other_name>glycoprotein IIb/IIIa inhibitors</other_name>
    <other_name>stent</other_name>
    <other_name>uncoated stent</other_name>
    <other_name>bare metal stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tirofiban and sirolimus-eluting stent</intervention_name>
    <description>Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation</description>
    <arm_group_label>4</arm_group_label>
    <other_name>glycoprotein IIb/IIIa inhibitors</other_name>
    <other_name>stent</other_name>
    <other_name>drug-eluting stent</other_name>
    <other_name>sirolimus-eluting stent</other_name>
    <other_name>DES</other_name>
    <other_name>SES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST segment elevation myocardial infarction

          -  Schedule for primary percutaneous coronary intervention

          -  Informed consent

        Exclusion Criteria:

          -  Administration of fibrinolytic or any GP IIb/IIIa inhibitors for the treatment of
             current acute myocardial infarction or within 1 month before it

          -  History of bleeding diathesis or allergy to the studies drug

          -  Major surgery within 30 days

          -  Limited life expectancy, e.g. neoplasms, others

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Ferrari, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Cattedra di Cardiologia, Azienda Ospedaliera Universitaria di Ferrara, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cattedra di Cardiologia, Azienda Ospedaliera Universitaria di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R; STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005 May 4;293(17):2109-17.</citation>
    <PMID>15870414</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <last_update_submitted>October 26, 2011</last_update_submitted>
  <last_update_submitted_qc>October 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Ferrara</investigator_affiliation>
    <investigator_full_name>Marco Valgimigli</investigator_full_name>
    <investigator_title>Head of the Catheterization laboratory</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Revascularization</keyword>
  <keyword>Stent</keyword>
  <keyword>ST segment elevation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Krestin</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Tirofiban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

